Minah Kim Lab

Publications

  • Kim S, Armand J, Safonov A, Zhang M, Soni RK, Schwartz G, McGuinness JE, Hibshoosh H, Razavi P, Kim M, Chandarlapaty S, Yang HW. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Rep. 2023 Nov 28;42(11):113198. doi: 10.1016/j.celrep.2023.113198. Epub 2023 Oct 21. PubMed PMID: 37865915.
  • Lee E*, O'Keefe S*, Leong A*, Park HR, Varadarajan J, Chowdhury S, Hiner S, Kim S, Shiva A, Friedman RA, Remotti H, Fojo T, Yang HW, Thurston G, Kim M. Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment. J Clin Invest. 2023 Oct 16;133(20). doi: 10.1172/JCI167994. PubMed PMID: 37843277.
  • Kim S, Carvajal R, Kim M, Yang HW. Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. Cell Rep. 2023 Jun 27;42(6):112570. doi: 10.1016/j.celrep.2023.112570. Epub 2023 May 29. PubMed PMID: 37252843.
  • Park HR*, Shiva A*, Cummings P, Kim S, Kim S, Lee E, Leong A, Chowdhury S, Shawber C, Carvajal R, Thurston G, An JY, Lund AW, Yang HW, Kim M. Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma. Cancer Res. 2023 Jun 15;83(12):1968-1983. PubMed PMID: 37093870; PubMed Central PMCID: PMC10267677 (Cover article)
  • Kim S, Leong A, Kim M#, Yang HW#. CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition. Sci Rep. 2022 Oct 7;12(1):16810. PubMed PMID: 36207346; PubMed Central PMCID: PMC9546874.
  • Inoue M*, Kim M*,Inoue T*, Tait M, Byrne T, Nitschké M, Murer P, Cha H, Subramanian A, De Silva N, Chiaverotti T, McDonald DM. Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade. Mol Ther Oncolytics. 2022 Mar 17;24:299-318. PubMed PMID: 35118189; PubMed Central PMCID: PMC8783073.
  • Leong A*, Kim M. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. Int J Mol Sci. 2020 Nov 18;21(22). PubMed PMID: 33217955; PubMed Central PMCID: PMC7698611.
  • Kim M*, Nitschké M*, Sennino B*, Murer P, Schriver BJ, Bell A, Subramanian A, McDonald CE, Wang J, Cha H, Bourgeois-Daigneault MC, Kirn DH, Bell JC, De Silva N, Breitbach CJ, McDonald DM. Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. Cancer Res. 2018 Feb 15;78(4):922-937. PubMed PMID: 29259007; PubMed Central PMCID: PMC6501576.
  • Kim M, Allen B, Korhonen EA, Nitschké M, Yang HW, Baluk P, Saharinen P, Alitalo K, Daly C, Thurston G, McDonald DM. Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. J Clin Invest. 2016 Sep 1;126(9):3511-25. PubMed PMID: 27548529; PubMed Central PMCID: PMC5004955.
  • Kim M*, Park HJ*, Seol JW*, Jang JY, Cho YS, Kim KR, Choi Y, Lydon JP, Demayo FJ, Shibuya M, Ferrara N, Sung HK, Nagy A, Alitalo K, Koh GY. VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. EMBO Mol Med. 2013 Sep;5(9):1415-30. PubMed PMID: 23853117; PubMed Central PMCID: PMC3799495. (Cover article)
  • Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, Alitalo K, Kim I, Koh GY. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res. 2010 Dec 15;70(24):10411-21. PubMed PMID: 21056990.